These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. Sheyman AT; Cohen BZ; Friedman AH; Ackert JM JAMA Ophthalmol; 2013 Jul; 131(7):864-9. PubMed ID: 23640384 [TBL] [Abstract][Full Text] [Related]
6. Assessment of the risk of needlestick injuries associated with intravitreal injections. Shah SU; Koenig MJ; Dacquay Y; Mozayan A; Hubschman JP Retina; 2014 Apr; 34(4):781-4. PubMed ID: 23975000 [TBL] [Abstract][Full Text] [Related]
7. Association of compounded bevacizumab with postinjection endophthalmitis. VanderBeek BL; Bonaffini SG; Ma L JAMA Ophthalmol; 2015 Oct; 133(10):1159-64. PubMed ID: 26270251 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab for Intravitreal Injection: Impact of Sub-Visible Particles on the Shelf-Life of Repackaged Bevacizumab. Crul M; Zandvliet A; Moes JR; Veenbaas T; Smeets O J Ocul Pharmacol Ther; 2019; 35(6):372-375. PubMed ID: 31259653 [No Abstract] [Full Text] [Related]
9. Quantification and structure elucidation of in vivo bevacizumab modification in rabbit vitreous humor after intravitreal injection. Chu KO; Liu DT; Chan KP; Yang YP; Yam GH; Rogers MS; Pang CP Mol Pharm; 2012 Dec; 9(12):3422-33. PubMed ID: 23094698 [TBL] [Abstract][Full Text] [Related]
10. Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration. Paul M; Vieillard V; Roumi E; Cauvin A; Despiau MC; Laurent M; Astier A Ann Pharm Fr; 2012 May; 70(3):139-54. PubMed ID: 22655582 [TBL] [Abstract][Full Text] [Related]
11. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. Wang F; Yu S; Liu K; Chen FE; Song Z; Zhang X; Xu X; Sun X Ophthalmology; 2013 Feb; 120(2):355-61. PubMed ID: 23084126 [TBL] [Abstract][Full Text] [Related]
12. Accuracy, precision and repeatability in preparing the intravitreal dose with a 1.0-cc syringe. Meyer CH; Liu Z; Brinkmann C; Rodrigues EB; Helb HM Acta Ophthalmol; 2012 Mar; 90(2):e165-6. PubMed ID: 21470379 [No Abstract] [Full Text] [Related]
14. Silicone oil droplets in repackaged anti-vascular endothelial growth factors for intravitreal injections: In search of the main source of contamination. Olea JL; Gómez-Resa M; Cervera-Peris MM; Aragón JA Eur J Ophthalmol; 2020 Jul; 30(4):774-779. PubMed ID: 30642195 [TBL] [Abstract][Full Text] [Related]
15. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Liu L; Ammar DA; Ross LA; Mandava N; Kahook MY; Carpenter JF Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):1023-34. PubMed ID: 21051703 [TBL] [Abstract][Full Text] [Related]
16. Quality of bevacizumab (Avastin®) repacked in single-use glass vials for intravitreal administration. Sugimoto MAA; Toledo VPCP; Cunha MRR; Carregal VM; Jorge R; Leão P; Fialho SL; Silva-Cunha A Arq Bras Oftalmol; 2017; 80(2):108-113. PubMed ID: 28591284 [TBL] [Abstract][Full Text] [Related]
17. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Roh MI; Kim HS; Song JH; Lim JB; Kwon OW Ophthalmology; 2009 Jan; 116(1):80-6. PubMed ID: 19118699 [TBL] [Abstract][Full Text] [Related]
18. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261 [TBL] [Abstract][Full Text] [Related]
19. Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab. Lee SH; Woo SJ; Park KH; Kim JH; Song JH; Park KU; Heo JW; Yu HG; Yu YS; Chung H Eye (Lond); 2010 Feb; 24(2):226-32. PubMed ID: 19407833 [TBL] [Abstract][Full Text] [Related]
20. Establishing benchmark rates of microbial and bacterial endotoxin contamination for radiopharmaceuticals compounded in commercial nuclear pharmacy settings. Weatherman KD; Augustine S; Christoff J; Galbraith W Int J Pharm Compd; 2013; 17(2):168-74. PubMed ID: 23696179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]